← Leaderboards
Geoffrey F Joyce
Rand Corporation
$1,347,497
Attributed
$1,347,497
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $484.7K · FY2019–21$500K$375K$250K$125K$0
'19
'20
'21
Funding mix
By agency
NIH$1,347,497 · 1
AHRQ$0 · 1
By mechanism
R01$1,347,497 · 1
R03$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Rand Corporation
Same institution · by research overlap
- Julie M Zissimopoulos$11,179,780
- James Patrick Smith$45,667,935
- Dana P Goldman$26,931,376
- Nicole A Maestas$13,244,181
- Allison Ober$4,010,165
Others in their field
Top investigators on “Health Insurance”
- Bruce J Hillman · American College Of Radiology$58,852,329
- Daniel Ernest Ford · Johns Hopkins University$57,376,797
- Arie Kapteyn · Rand Corporation$56,582,668
- Robert J Willis · University Of Michigan At Ann Arbor$54,158,444
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$53,240,903
- Steven M. Dubinett · Va Greater Los Angeles Healthcare System$51,151,821
Research focus
Health InsuranceHealth Care Service UtilizationDrug UsageBaseAdministrative DatabaseBeneficiaryCare CostsComplementCare OutcomesCaringCase-Control StudiesAgingChronicChronic DiseaseCardiovascular DiseasesAlternative TreatmentCongestive Heart FailureCostCost SharingDatabasesDesignDiabetes MellitusDiagnosisAffect
Grant awards (4)
Evidence for Value-based Prescription Drug Plan for Diabetes, CVD and Chronic Illness$431,384
R01 · FY2021 · AG · contact PI
Evidence for Value-based Prescription Drug Plan for Diabetes, CVD and Chronic Illness$431,384
R01 · FY2020 · AG · contact PI
Evidence for Value-based Prescription Drug Plan for Diabetes, CVD and Chronic Illness$484,729
R01 · FY2019 · AG · contact PI
Impact of Drug Benefit Design on Utilization and Cost$0
R03 · FY2002 · HS